(ENX) Euronext - Ratings and Ratios
Securities, Derivatives, Data, Listing, Trading
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.01% |
| Yield on Cost 5y | 3.95% |
| Yield CAGR 5y | 18.51% |
| Payout Consistency | 98.7% |
| Payout Ratio | 45.7% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 17.5% |
| Value at Risk 5%th | 28.6% |
| Relative Tail Risk | -1.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.44 |
| Alpha | 7.71 |
| CAGR/Max DD | 0.88 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.489 |
| Beta | -0.002 |
| Beta Downside | -0.002 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.72% |
| Mean DD | 6.42% |
| Median DD | 3.21% |
Description: ENX Euronext January 03, 2026
Euronext N.V. (ENX) operates a pan-European network of securities and derivatives exchanges across ten countries, offering cash and derivatives trading, listing services, market-data distribution, and a suite of post-trade and technology solutions for market participants.
Key performance indicators from FY 2023 show net revenue of €1.18 billion, a 7 % year-over-year increase driven primarily by higher derivatives turnover and expanded data-service contracts, while the company posted an adjusted EBITDA margin of 45 % and paid a dividend yielding roughly 5 %.
Sector drivers that materially affect ENX’s outlook include the continued implementation of EU MiFID II and MiFIR regulations, which boost demand for compliant trading infrastructure, and the accelerating shift toward electronic and ESG-focused products that expands the addressable market for both cash equities and commodity-linked derivatives.
For a deeper quantitative assessment, you might explore ValueRay’s analyst tools to model ENX’s valuation under different market scenarios.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 642.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -0.03 > 1.0 |
| NWC/Revenue: -8806 % < 20% (prev 54.33%; Δ -8860 % < -1%) |
| CFO/TA 0.00 > 3% & CFO 928.7m > Net Income 642.8m |
| Net Debt (1.77b) to EBITDA (1.14b): 1.55 < 3 |
| Current Ratio: 0.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.7m) vs 12m ago -1.50% < -2% |
| Gross Margin: 83.52% > 18% (prev 0.55%; Δ 8297 % > 0.5%) |
| Asset Turnover: 0.57% > 50% (prev 0.61%; Δ -0.05% > 0%) |
| Interest Coverage Ratio: 348.3 > 6 (EBITDA TTM 1.14b / Interest Expense TTM 2.72m) |
Altman Z'' -2.76
| A: -0.43 (Total Current Assets 202.74b - Total Current Liabilities 359.25b) / Total Assets 366.65b |
| B: 0.01 (Retained Earnings 1.84b / Total Assets 366.65b) |
| C: 0.00 (EBIT TTM 946.2m / Avg Total Assets 312.30b) |
| D: 0.01 (Book Value of Equity 2.15b / Total Liabilities 362.20b) |
| Altman-Z'' Score: -2.76 = D |
Beneish M 1.00
| DSRI: 0.84 (Receivables 433.4m/457.8m, Revenue 1.78b/1.58b) |
| GMI: 0.66 (GM 83.52% / 55.29%) |
| AQI: 17.99 (AQ_t 0.45 / AQ_t-1 0.02) |
| SGI: 1.12 (Revenue 1.78b / 1.58b) |
| TATA: -0.00 (NI 642.8m - CFO 928.7m) / TA 366.65b) |
| Beneish M-Score: 6.70 (Cap -4..+1) = D |
ValueRay F-Score (Strict, 0-100) 80.48
| 1. Piotroski: 5.50pt |
| 2. FCF Yield: 5.97% |
| 3. FCF Margin: 48.14% |
| 4. Debt/Equity: 0.70 |
| 5. Debt/Ebitda: 1.55 |
| 6. ROIC - WACC: 4.83% |
| 7. RoE: 15.19% |
| 8. Revenue Trend: 75.35% |
| 9. EPS Trend: 68.24% |
What is the price of ENX shares?
Over the past week, the price has changed by -3.04%, over one month by -4.79%, over three months by -4.56% and over the past year by +12.29%.
Is ENX a buy, sell or hold?
What are the forecasts/targets for the ENX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 147.6 | 21.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 135.7 | 11.9% |
ENX Fundamental Data Overview January 19, 2026
P/E Trailing = 19.1811
P/E Forward = 15.5039
P/S = 7.102
P/B = 2.9371
P/EG = 2.1522
Revenue TTM = 1.78b EUR
EBIT TTM = 946.2m EUR
EBITDA TTM = 1.14b EUR
Long Term Debt = 2.54b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 630.9m EUR (from shortTermDebt, last quarter)
Debt = 3.01b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.77b EUR (from netDebt column, last quarter)
Enterprise Value = 14.33b EUR (12.63b + Debt 3.01b - CCE 1.31b)
Interest Coverage Ratio = 348.3 (Ebit TTM 946.2m / Interest Expense TTM 2.72m)
EV/FCF = 16.75x (Enterprise Value 14.33b / FCF TTM 855.6m)
FCF Yield = 5.97% (FCF TTM 855.6m / Enterprise Value 14.33b)
FCF Margin = 48.14% (FCF TTM 855.6m / Revenue TTM 1.78b)
Net Margin = 36.17% (Net Income TTM 642.8m / Revenue TTM 1.78b)
Gross Margin = 83.52% ((Revenue TTM 1.78b - Cost of Revenue TTM 292.9m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 87.58%)
Tobins Q-Ratio = 0.04 (Enterprise Value 14.33b / Total Assets 366.65b)
Interest Expense / Debt = 0.04% (Interest Expense 1.22m / Debt 3.01b)
Taxrate = 26.70% (58.5m / 219.1m)
NOPAT = 693.6m (EBIT 946.2m * (1 - 26.70%))
Current Ratio = 0.56 (Total Current Assets 202.74b / Total Current Liabilities 359.25b)
Debt / Equity = 0.70 (Debt 3.01b / totalStockholderEquity, last quarter 4.30b)
Debt / EBITDA = 1.55 (Net Debt 1.77b / EBITDA 1.14b)
Debt / FCF = 2.07 (Net Debt 1.77b / FCF TTM 855.6m)
Total Stockholder Equity = 4.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.21% (Net Income 642.8m / Total Assets 366.65b)
RoE = 15.19% (Net Income TTM 642.8m / Total Stockholder Equity 4.23b)
RoCE = 13.98% (EBIT 946.2m / Capital Employed (Equity 4.23b + L.T.Debt 2.54b))
RoIC = 9.61% (NOPAT 693.6m / Invested Capital 7.22b)
WACC = 4.78% (E(12.63b)/V(15.64b) * Re(5.91%) + D(3.01b)/V(15.64b) * Rd(0.04%) * (1-Tc(0.27)))
Discount Rate = 5.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.75%
[DCF Debug] Terminal Value 87.39% ; FCFF base≈788.9m ; Y1≈884.2m ; Y5≈1.18b
Fair Price DCF = 317.2 (EV 34.66b - Net Debt 1.77b = Equity 32.89b / Shares 103.7m; r=5.90% [WACC]; 5y FCF grow 14.01% → 2.90% )
EPS Correlation: 68.24 | EPS CAGR: 6.39% | SUE: 0.0 | # QB: 0
Revenue Correlation: 75.35 | Revenue CAGR: 4.97% | SUE: -0.37 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.87 | Chg30d=-0.056 | Revisions Net=-2 | Analysts=3
EPS next Year (2026-12-31): EPS=7.73 | Chg30d=+0.003 | Revisions Net=+0 | Growth EPS=+7.4% | Growth Revenue=+6.6%